Core Viewpoint - The company has updated its share buyback plan to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025, indicating confidence in its long-term growth and market performance [1] Group 1: Share Buyback Plan - The updated share buyback plan represents 5% of the total issued shares as of the authorization date in 2025 [1] - The board believes the current share price does not reflect the company's true value and business prospects [1] - The buyback plan is seen as being in the best interest of the company and its shareholders [1] Group 2: Shareholding Update - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, the Yijie concert group holds 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) as of the announcement date [1]
科济药业-B拟回购最多约2546.13万股股份 获主要股东增持10万股股份